These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38317525)

  • 1. Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan.
    Miyazaki C; Masuda J; Rodriguez-Rey MD; Stelmaszuk MN; Freilich J; Tsai PI; Saeki H
    J Dermatolog Treat; 2024 Dec; 35(1):2299598. PubMed ID: 38317525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study.
    Tada Y; Kim H; Spanopoulos D; Habiro K; Tsuritani K; Yamada Y; Mandal A; Zhong Y; Hikichi Y
    J Dermatol; 2022 Nov; 49(11):1106-1117. PubMed ID: 35946343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization.
    Poulin Y; Beauchemin C; Royer C; Gaudreau AJ; Yim C; Liu FF; Lachaine J
    J Cutan Med Surg; 2020; 24(6):573-587. PubMed ID: 32597685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
    Foster SA; Zhu B; Guo J; Nikai E; Ojeh C; Malatestinic W; Goldblum O; Kornberg LJ; Wu JJ
    J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
    Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
    J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
    Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour T; Kern S; Lew C; Zimmerman N; Murage M
    Clin Drug Investig; 2023 Mar; 43(3):185-196. PubMed ID: 36840815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study.
    Miyazaki C; Sruamsiri R; Mahlich J; Jung W
    PLoS One; 2020; 15(5):e0232738. PubMed ID: 32442204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Claims Analyses of Comorbidity Burden, Treatment Pattern, Healthcare Resource Utilization, and Costs in Pediatric Psoriasis.
    Edson-Heredia E; Anderson S; Guo J; Zhu B; Malatestinic WN; Wine-Lee L; Swanson E
    Adv Ther; 2021 Jul; 38(7):3948-3961. PubMed ID: 34091866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
    Blauvelt A; Shi N; Murage MJ; Kern SA; Somani N; Burge R; Ridenour TL; Lew CR; Zimmerman NM; Zhu B
    J Med Econ; 2022; 25(1):741-749. PubMed ID: 35615978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
    Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
    Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
    Sruamsiri R; Iwasaki K; Tang W; Mahlich J
    BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
    Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
    J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis.
    Wu JJ; Wang CA; Jobson G; Davidson D; Kalirai S; Zhu J; Suryavanshi M; Mittal M; Patel V; Seigel L
    J Dermatolog Treat; 2023 Dec; 34(1):2177095. PubMed ID: 36736349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs.
    Dignass A; Waller J; Cappelleri JC; Modesto I; Kisser A; Dietz L; DiBonaventura M; Wood R; May M; Libutzki B; Bargo D
    J Med Econ; 2020 Apr; 23(4):415-427. PubMed ID: 31858853
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database.
    Pina Vegas L; Penso L; Claudepierre P; Sbidian E
    JAMA Dermatol; 2022 May; 158(5):513-522. PubMed ID: 35319735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
    Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
    Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Care Utilization and Cost Associated with Biologic Treatment Patterns Among Patients with Moderate to Severe Psoriasis: Analyses from a Large U.S. Claims Database.
    Feldman SR; Tian H; Wang X; Germino R
    J Manag Care Spec Pharm; 2019 Apr; 25(4):479-488. PubMed ID: 30556761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
    Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
    Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.
    Armstrong AW; Foster SA; Comer BS; Lin CY; Malatestinic W; Burge R; Goldblum O
    BMC Dermatol; 2018 Jun; 18(1):4. PubMed ID: 29954363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.